Lyme Vaccine Filings Advance in Europe, Canada

Adults in tick-endemic areas may eventually have a new prevention option, though no approval timeline has been set.

Updated on Nov. 4, 2026 in COVID-19

Isometric editorial illustration of an unlabeled glass vial on a bed of forest-floor leaves, with a small tick on a fern in the background.
Pfizer and partner Valneva have filed their Lyme disease vaccine with regulators in Europe and Canada, while talks with U.S. regulators continue without a set approval timeline. AI Illustration. Upload story photo >

Live Poll

Would you get a Lyme disease vaccine if one became available in your area?

Pfizer discussed regulatory plans for its Lyme disease vaccine, developed with partner Valneva, on its third-quarter earnings call. The European Medicines Agency confirmed receipt of the application in August, and the vaccine has also been filed in Canada, while talks with U.S. regulators are ongoing.

Why it matters

Lyme disease is a tick-borne illness whose incidence and severity are rising in the United States, so a licensed vaccine would add a prevention option for people in endemic areas. Timelines remain uncertain, so any approval is still some way off.

The reported information concerns regulatory status rather than clinical results, with no trial design, sample size, or efficacy measurements included in the source. The filings and discussions described are preliminary and do not yet establish how well the vaccine performs.

The players

Pfizer

A major pharmaceutical company with a broad portfolio of vaccines and treatments, including a tick-borne encephalitis vaccine marketed in Europe.

Valneva

A vaccine developer that is Pfizer's partner on the Lyme disease vaccine candidate.

European Medicines Agency

The European Union agency responsible for scientific evaluation of medicines and vaccines, which confirmed receipt of the application.

The details

Pfizer plans to commercialize the vaccine in Europe by using its existing sales force and pharmacy relationships in tick-borne endemic areas. The European regulatory review began after the EMA confirmed receipt of the application in August, and the review is set to conclude with a verdict from the CHMP in 2027.

Timeline

  1. August: The EMA confirmed receipt of Pfizer's Lyme disease vaccine application.

  2. Q4 2026: Pfizer discussed Lyme vaccine regulatory plans on its third-quarter earnings call, with an update on U.S. discussions expected this quarter.

  3. End of 2026: Analysts suggest the FDA filing could be completed.

  4. 2027: The CHMP is set to deliver its verdict on European approval.

Health Landscape

Lyme disease has no widely used human vaccine in the United States, so this application would be a first if approved, placing it among a small set of candidates targeting the disease. The filing reflects a broader push to address tick-borne infections as their incidence in the U.S. rises.

If you live in or travel to a tick-endemic area, this is worth tracking as a possible future prevention option, though it is not yet approved anywhere. Keep up tick-prevention habits in the meantime, and ask your doctor about Lyme risk and prevention if you spend time outdoors.

The takeaway

Lyme vaccine approval remains a multi-year process, so current protection still depends on tick prevention. Ask your physician about Lyme risk if you spend time in wooded or grassy areas.

What happens next

The European review will conclude with a CHMP verdict in 2027, and an update on U.S. regulatory discussions is expected this quarter.

Further reading

For broader context on how vaccines move through regulatory review, explore our COVID-19 coverage.

Source note: This article includes information reported by Pharma.

Live Poll

Would you get a Lyme disease vaccine if one became available in your area?